Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000077972 | SCV000109801 | pathogenic | not provided | 2013-03-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001078885 | SCV001099710 | likely benign | Muscle AMP deaminase deficiency | 2024-01-01 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782049 | SCV005395717 | uncertain significance | not specified | 2024-09-04 | criteria provided, single submitter | clinical testing | Variant summary: AMPD1 c.35-7_35-4delCTTT alters conserved nucleotides located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00054 in 251474 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in AMPD1 causing Muscle AMP Deaminase Deficiency, allowing no conclusion about variant significance. c.35-7_35-4delCTTT has been reported in the literature in two siblings affected with Myoadenylate deaminase deficiency by only screening AMPD1 gene (Isackson_2005). These report(s) do not provide unequivocal conclusions about association of the variant with Muscle AMP Deaminase Deficiency. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 16040263). ClinVar contains an entry for this variant (Variation ID: 92332). Based on the evidence outlined above, the variant was classified as uncertain significance. |